Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

PURPOSE: Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30.CAR-Ts) can be used to treat Hodgkin lymphoma (HL). METHODS: We conducted 2 parallel phase I/II studies (ClinicalTrials.gov...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ramos, Carlos A., Grover, Natalie S., Beaven, Anne W., Lulla, Premal D., Wu, Meng-Fen, Ivanova, Anastasia, Wang, Tao, Shea, Thomas C., Rooney, Cliona M., Dittus, Christopher, Park, Steven I., Gee, Adrian P., Eldridge, Paul W., McKay, Kathryn L., Mehta, Birju, Cheng, Catherine J., Buchanan, Faith B., Grilley, Bambi J., Morrison, Kaitlin, Brenner, Malcolm K., Serody, Jonathan S., Dotti, Gianpietro, Heslop, Helen E., Savoldo, Barbara
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655020/
https://ncbi.nlm.nih.gov/pubmed/32701411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01342
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados